Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPY4R | P50391 | 5/20 | 0.44 |
| ▸ | NPY1R | P25929 | 3/20 | 0.44 |
| ▸ | DPP7 | Q9UHL4 | 2/20 | 0.44 |
| ▸ | GNAI3 | P08754 | 1/20 | 0.42 |
| ▸ | GNAO1 | P09471 | 1/20 | 0.42 |
| ▸ | GNAI1 | P63096 | 1/20 | 0.42 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | RRM1 | P23921 | 1/20 | 0.37 |
| ▸ | NPY2R | P49146 | 2/20 | 0.37 |
| ▸ | NPY5R | Q15761 | 2/20 | 0.37 |
| ▸ | CA12 | O43570 | 3/20 | 0.36 |
| ▸ | CA1 | P00915 | 3/20 | 0.36 |
| ▸ | CA2 | P00918 | 3/20 | 0.36 |
| ▸ | CA9 | Q16790 | 3/20 | 0.36 |
| ▸ | NOS3 | P29474 | 1/20 | 0.35 |
| ▸ | NOS1 | P29475 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4094683 | 1.00 | NPY4R (0.44) | NPY4RNPY1RDPP7GNAI3GNAO1 | |
| Hydrochloric Acid SCHEMBL940707 | 0.98 | NPY4R (0.43) | NPY4RNPY1RDPP7GNAI3GNAO1 | |
| SCHEMBL42488 | 0.95 | NPY4R (0.45) | NPY4RNPY1RDPP7GNAI3GNAO1 | |
| SCHEMBL157856 | 0.95 | NPY4R (0.45) | NPY4RNPY1RDPP7GNAI3GNAO1 | |
| SCHEMBL2172217 | 0.95 | NPY4R (0.45) | NPY4RNPY1RDPP7GNAI3GNAO1 | |
| Urea SCHEMBL6812514 | 0.93 | NPY4R (0.44) | NPY4RNPY1RDPP7GNAI3GNAO1 | |
| Hydrochloric Acid SCHEMBL940540 | 0.93 | NPY4R (0.44) | NPY4RNPY1RDPP7GNAI3GNAO1 | |
| Hydrochloric Acid SCHEMBL866931 | 0.93 | NPY4R (0.44) | NPY4RNPY1RDPP7GNAI3GNAO1 | |
| Guanidine SCHEMBL8907224 | 0.93 | NPY4R (0.44) | NPY4RNPY1RDPP7GNAI3GNAO1 | |
| Hydrochloric Acid SCHEMBL940539 | 0.93 | NPY4R (0.44) | NPY4RNPY1RDPP7GNAI3GNAO1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12521455-B2 | Kisspeptin receptor (KISS1R) targeted therapeutics and uses thereof | RADIONETICS ONCOLOGY, INC. (US) | 2026-01-13 | — | — | US | claimed |
| WO-2025217074-A1 | KISSPEPTIN RECEPTOR (KISS1R) TARGETED THERAPEUTICS AND USES THEREOF | RADIONETICS ONCOLOGY, INC. (US) | 2025-10-16 | — | — | WO | claimed |
| US-20250312499-A1 | KISSPEPTIN RECEPTOR (KISS1R) TARGETED THERAPEUTICS AND USES THEREOF | RADIONETICS ONCOLOGY, INC. | 2025-10-09 | — | — | US | claimed |
| WO-2024206577-A1 | KISSPEPTIN RECEPTOR (KISS1R) TARGETED THERAPEUTICS AND USES THEREOF | RADIONETICS ONCOLOGY, INC. (US) | 2024-10-03 | — | — | WO | claimed |
| US-12521455-B2 | Kisspeptin receptor (KISS1R) targeted therapeutics and uses thereof | RADIONETICS ONCOLOGY, INC. (US) | 2026-01-13 | — | — | US | disclosed |
| WO-2025217074-A1 | KISSPEPTIN RECEPTOR (KISS1R) TARGETED THERAPEUTICS AND USES THEREOF | RADIONETICS ONCOLOGY, INC. (US) | 2025-10-16 | — | — | WO | disclosed |
| US-20250312499-A1 | KISSPEPTIN RECEPTOR (KISS1R) TARGETED THERAPEUTICS AND USES THEREOF | RADIONETICS ONCOLOGY, INC. | 2025-10-09 | — | — | US | disclosed |
| WO-2024206577-A1 | KISSPEPTIN RECEPTOR (KISS1R) TARGETED THERAPEUTICS AND USES THEREOF | RADIONETICS ONCOLOGY, INC. (US) | 2024-10-03 | — | — | WO | disclosed |
| EP-2193204-B1 | COMPOSITIONS COMPRISING LIPOPHOSPHORAMIDES AND THEIR USES IN GENE THERAPY | UNIV BRETAGNE OCCIDENTALE (FR) | 2011-08-31 | — | — | EP | disclosed |
| US-20110008415-A1 | NOVEL LIPOPHILIC COMPOSITIONS AND USES THEREOF | UNIVERSITE DE BRETAGNE OCCIDENTALE (FR) | 2011-01-13 | — | — | US | disclosed |
| EP-1575900-A4 | N-METHYL AMINO ACIDS | UBIQUITOUS TECHNOLOGIES PTY LT (AU) | 2007-02-21 | — | — | EP | disclosed |
| EP-1575900-A1 | N-METHYL AMINO ACIDS | UBIQUITOUS TECHNOLOGIES PTY LTD (AU) | 2005-09-21 | — | — | EP | disclosed |
| WO-2004007427-A1 | N-METHYL AMINO ACIDS | UBIQUITOUS TECHNOLOGIES PTY LTD (AU) | 2004-01-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110008415-A1 | NOVEL LIPOPHILIC COMPOSITIONS AND USES THEREOF | LIPA, NPC1L1, PLTP | NPY4R 4458/4885NPY1R 4382/4885DPP7 2191/4885 |
| US-20250312499-A1 | KISSPEPTIN RECEPTOR (KISS1R) TARGETED THERAPEUTICS AND USES THEREOF | KISS1R, GNRHR, PROKR1 | NPY4R 21/4885NPY1R 8/4885DPP7 410/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.